Recombinant human brain natriuretic peptide in acute decompensated heart failure
10.13699/j.cnki.1001-6821.2019.08.002
- VernacularTitle:重组人脑利钠肽治疗老年急性失代偿心力衰竭的临床研究
- Author:
Na-Li LI
1
;
Ya-Jun CHEN
;
Huai-Zhen WANG
;
Jin WEI
Author Information
1. 天津市第三中心医院
- Keywords:
acute decompensated heart failure;
recombinant human brain natriuretic peptide;
older
- From:
The Chinese Journal of Clinical Pharmacology
2019;35(8):734-736
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical efficacy and safety of recombinant human brain natriuretic peptide (rhBNP) in older patients with acute decompensated heart failure. Methods A total of 86 aged patients with acute decompensated heart failure who admitted to our hospital were enrolled. First, they were given recombinant human brain natriuretic peptide (rhBNP) loading doses 1. 5 μg·kg-1,3-5 min, intravenous injection, then continuous intravenous pump 0. 015 kg-1 for 3-5 days. The brain natriuretic peptide(BNP) ,left ventricular ejection fraction(LVEF) and blood urea nitrogen(BUN) ,serum creatinine(SCr) ,urine output/ intake ratio and blood pressure were compared befor and after treatment one week. Result Before and after treatment,BNP was(2387. 50 ± 1030. 99) pg·mL-1 and (783. 57 ± 476. 71) pg·mL-1; LVEF was(40. 85 ± 8. 76) ％ and(44. 35 ± 0. 94) ％; the systolic blood pressure was (135. 21 ± 15. 58) mmHg and(127. 51 ± 16. 24) mmHg; the urine output/ intake ratio was (0. 81 ± 0. 50) and (1. 26 ± 0. 24). Statistically significant differences before and after treatment were found(all P < 0. 05). Conclusion The early application of rhBNP in older patients with acute decompensated heart failure is effective and safe. It can improve cardiac function,and has no adverse effect on renal function,and increases urine output.
